Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
2.440
+0.020 (0.83%)
At close: Oct 9, 2026, 4:00 PM EDT
2.480
+0.040 (1.64%)
After-hours: Oct 9, 2026, 7:36 PM EDT
Atossa Therapeutics Employees
Atossa Therapeutics had 16 employees as of December 31, 2025. The number of employees increased by 1 or 6.67% compared to the previous year. That makes Atossa Therapeutics the 38,856th largest employer in the world and 5,656th in the United States.
Employees
16
Change (1Y)
1
Growth (1Y)
6.67%
Revenue / Employee
n/a
Profits / Employee
-$2,356,813
Market Cap
24.35M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 16 | 1 | 6.67% | 16 | 0 |
| Dec 31, 2024 | 15 | 3 | 25.00% | 15 | 0 |
| Dec 31, 2023 | 12 | 1 | 9.09% | 12 | 0 |
| Dec 31, 2022 | 11 | 3 | 37.50% | 11 | 0 |
| Dec 31, 2021 | 8 | 0 | - | 6 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Seres Therapeutics | 66 |
| aTyr Pharma | 60 |
| Evaxion | 46 |
| BeyondSpring | 44 |
| Kyntra Bio | 34 |
| ABVC BioPharma | 19 |
| Quantum BioPharma | 17 |
| Context Therapeutics | 15 |
ATOS News
- 1 day ago - Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value - PRNewsWire
- 11 days ago - Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher - PRNewsWire
- 16 days ago - Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging - PRNewsWire
- 22 days ago - Atossa Therapeutics Slides: Corporate presentation - Filings
- 2 months ago - Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - PRNewsWire
- 2 months ago - Atossa Therapeutics Quarterly report: Q2 2026 - Filings
- 2 months ago - Atossa Therapeutics Earnings release: Q2 2026 - Filings
- 2 months ago - Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer - PRNewsWire